TMCnet News
BIND Therapeutics to Report Fourth Quarter and Year-End 2014 Financial Results on March 11, 2015BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced it will host a conference call and live audio webcast on March 11, 2015, at 8:30 a.m. ET to report fourth quarter and year-end 2014 financial results. To access the conference call, please dial (877) 312-5844 (domestic) or (253) 237-1152 (international) at least five minutes prior to the start time and refer to conference ID 88372910. A live audio webcast of the call will also be available on the Investors & Media section of the Company's website, www.bindtherapeutics.com. An archived webcast will be available on the Company's website approximately two hours after the event. About BIND Therapeutics BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins™, its novel targeted therapeutics. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd. and Merck (known as Merck Sharp (News - Alert) & Dohme outside the United States and Canada) to develop Accurins based on their proprietary therapeutic payloads and targeting ligands. For more information, please visit the Company's website at www.bindtherapeutics.com.
|
